Taxotere (docetaxel) is the most widely used breast cancer drug in its class, with up to 75% of breast cancer patients receiving the drug as a form of treatment. While many patients respond well to the drug, the drug may also have a distressing side effect for breast cancer survivors. Up to 9% of men and women who take Taxotere suffer from permanent hair loss, also called alopecia. While many people are aware of and expect temporary hair loss when undergoing chemotherapy, the manufacturer of the drug, Sanofi-Aventis failed to warn consumers or doctors that the resulting hair loss could be permanent. Even though Sanofi was aware of the permanent hair loss, that information was not included in its Prescribing Information for physicians.
Taxotere Hair Loss Claims
For men and women undergoing cancer treatment, even temporary hair loss can be devastating. For those experiencing unexpected, Taxotere permanent hair loss, the risk may have been enough for them to select alternative treatments. Of the thousands of people deprived of the opportunity to make an informed decision regarding their cancer treatment, many have filed suit in federal court.
On October 4, the U.S. Judicial Panel on Multidistrict Litigation ordered all federally filed Taxotere lawsuits alleging permanent, disfiguring alopecia be consolidated in the U.S. District Court, Eastern District of Louisiana. The centralization allows these claims, as well as any future filings, to undergo consolidated pretrial proceedings to avoid duplicative discovery and inconsistent rulings from courts situated in different states. Additional claimants who experienced Taxotere permanent hair loss during chemotherapy may be eligible to join the litigation.
Get Help With Lawsuits For Taxotere Permanent Hair Loss
If you or a loved one experienced permanent alopecia following chemotherapy with Taxotere, please contact The Lambert Firm today for a consultation with a Louisiana multi-district litigation attorney.